663P - Multicenter phase II trial of adjuvant S-1 plus docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG-1002)

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Gastric Cancer
Biological Therapy
Presenter Kazuyoshi Yamamoto
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors K. Yamamoto1, K. Fujitani2, S. Tamura3, J. Fujita4, J. Matsuyama5, Y. Kimura6, H. Imamura7, Y. Makari8, Y. Kurokawa9, T. Satoh10, T. Tsujinaka11, H. Furukawa12
  • 1Surgery, National Hospital Organization, Osaka National Hospital, 5400006 - Osaka/JP
  • 2Surgical Oncology, Osaka General Medical Center, Osaka/JP
  • 3Surgery, Kansai Rosai Hospital, 660-8511 - Amagasaki/JP
  • 4Surgery, NTT West Osaka Hospital, 543-8922 - Osaka/JP
  • 5Department Of Surgery, Yao Municipal Hospital, Yao/JP
  • 6Surgery, Sakai Municipal Hospital, Sakai/JP
  • 7Surgey, Toyonaka Municipal Hospital, Toyonaka/JP
  • 8Surgery, Minoh City Hospital, Minoh/JP
  • 9Gastroenterological Surgery, Osaka University, 565-0871 - Suita/JP
  • 10Frontier Science For Cancer And Chemotherapy, Osaka University Graduate School of Medicine, Suita/JP
  • 11Department Of Surgery, Kaizuka City Hospital, Kaizuka/JP
  • 12Surgery, Kinki University School of Medicine, Sayama/JP



We have previously indicated the torelability and safety of adjuvant S-1 plus Docetaxel for 3 months after D2 gastrectomy in patients with pathological stage III gastric cancer (OGSG-0604). To achieve the further treatment outcome, we conducted a phase II study to evaluate the feasibility of S-1 plus Docetaxel for 6 months after D2 gastrectomy in counterpart patients.


Eligibility criteria included ECOG-PS of 0 or 1, age between 20 and 80 years and histologically proven stage III gastric cancer after R0 gastrectomy with D2 lymphadenectomy. Enrolled patients received 40mg/m2 Docetaxel on day1 intravenously and 80mg/m2 oral S-1 on day1-14 every 3 weeks (one cycle). This 3–week cycle was repeated for 8 cycles (for 6 months), followed by S-1 monotherapy until 1 year after surgery. The primary endpoint was feasibility of S-1 plus Docetaxel for 8 cycles.


A total of 62 patients (32 stage IIIA, 30 IIIB, according to the 13th Japanese Classification of Gastric Carcinoma) were enrolled in this study from 14 institutes between Dec 2010 and Dec 2012. Forty-eight patients (77.4%, 95%CI 65.0-87.1%) completed the planned 8 cycles of S-1 plus Docetaxel and the proportion of patients completed planned cycles was comparable with that of 4 cycles (OGSG-0604). Forty-two patients completed the consequent S-1 monotherapy until 1 year after surgery and 2 patients were ongoing of consequent S-1 monotherapy. This doublet regimen was well tolerated, with 19% of Grade 4 neutropenia, 18% of Grade 3 anorexia and 10 % of Grade3 fatigue, while no febrile neutropenia, grade 4 non-hematological toxicities and treatment related death were observed.


Adjuvant S-1 plus Docetaxel for 6 months in patients with stage III gastric cancer was well tolerated after D2 gastrectomy and will be a candidate for future phase III trials studying the optimal adjuvant chemotherapy regimen for stage III gastric cancer.


All authors have declared no conflicts of interest.